Accriva Diagnostics, a portfolio company of Warburg Pincus, has named Scott Cramer as president and CEO, effective immediately. Currently, Cramer is the executive chairman of NeuWave Medical. Accriva Diagnostics is a provider of point-of-care cardiovascular diagnostics solutions.
SAN DIEGO–(BUSINESS WIRE)–Accriva Diagnostics, a leading hospital-based point-of-care (POC) cardiovascular diagnostics business, today announced that it has appointed Scott Cramer as President and Chief Executive officer effective immediately.
“We are excited that Scott’s proven record of producing rapid growth and results across many medical device businesses will help Accriva further enhance its position as a leading hospital-based cardiovascular diagnostic company.”
Mr. Cramer has over 30 years of commercial and operational excellence experience with medical device companies. He has held executive leadership positions for venture-backed companies throughout the cardiology, peripheral vascular and female health markets including President and CEO of Novasys Medical, Inc. and President and CEO of Bacchus Vascular, Inc.
In addition, Mr. Cramer has held other leadership positions in healthcare companies including Senior Vice President of U.S. Sales and Account Services for VNUS Medical Technologies, Vice President of U.S. Sales at EndoSonics Corporation, National Sales Manager at Cardiometrics, Inc., and several positions at Baxter Healthcare Corporation’s cardiovascular division. Mr. Cramer currently is Executive Chairman of NeuWave Medical and serves on the Board of Directors of Vascular Insights, AccuVein and Accriva. He has also held previous board directorships at Venous Health, Bacchus Vascular and Novasys Medical.
“We are pleased to welcome Scott to Accriva Diagnostics and look forward to his leadership,” said Joseph Nemmers, Chairman of Accriva Diagnostics. “We are excited that Scott’s proven record of producing rapid growth and results across many medical device businesses will help Accriva further enhance its position as a leading hospital-based cardiovascular diagnostic company.”
“I am very pleased to join Accriva Diagnostics at this critical juncture,” said Mr. Cramer. “This is an exciting time as we integrate two market leaders, ITC and Accumetrics, to form Accriva Diagnostics. The combination of ITC’s Hemochron® and Accumetrics’ VerifyNow® product lines, our strong industry reputation and numerous planned growth initiatives will create further value for our investors and our customers, and establish us as the leading hospital-based POC cardiovascular diagnostics company.”
About Accriva Diagnostics
Accriva Diagnostics is the result of ITC’s 2013 acquisition of Accumetrics. The combined strengths in coagulation monitoring (ITC) and platelet testing (Accumetrics) have created a leading point-of-care diagnostic company. The Accriva portfolio of products represent over 40 years of leadership and expertise in hemostasis management, including the development, manufacturing and marketing of Hemochron®, InRhythm™ and ProTime® Microcoagulation systems; the VerifyNow® system for assessment of platelet reactivity; IRMA TruPoint® Blood Gas and Electrolyte systems; Avoximeter®CO-Oximetry systems; Tenderfoot®, Tenderlett® and Surgicutt® skin incision products. Accriva is a portfolio company of Warburg Pincus, a global private equity firm focused on growth investing.
For more information about Accriva Diagnostics visit www.accriva.com.